VERTEX PHARMACEUTIC
VERTEX PHARMACEUTIC operates in Diversified Metals & Mining.
VERTEX PHARMACEUTIC (VX1) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2024: 0.088x
Based on the latest financial reports, VERTEX PHARMACEUTIC (VX1) has a cash flow conversion efficiency ratio of 0.088x as of September 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€1.37 Billion) by net assets (€15.63 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
VERTEX PHARMACEUTIC - Cash Flow Conversion Efficiency Trend (2016–2023)
This chart illustrates how VERTEX PHARMACEUTIC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
VERTEX PHARMACEUTIC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of VERTEX PHARMACEUTIC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Longvie SA
BA:LONG
|
-0.060x |
|
Carl Data Solutions Inc
OTCQB:CDTAF
|
0.223x |
|
Trisula International Tbk
JK:TRIS
|
0.121x |
|
Asra Minerals Ltd
AU:ASR
|
-0.050x |
|
AHB Holdings Bhd
KLSE:7315
|
-0.391x |
|
Wirtek A/S
CO:WIRTEK
|
-0.165x |
|
International Graphite Ltd
AU:IG6
|
-0.066x |
|
Uranium Valley Mines Ltd.
V:VZZ
|
0.077x |
Annual Cash Flow Conversion Efficiency for VERTEX PHARMACEUTIC (2016–2023)
The table below shows the annual cash flow conversion efficiency of VERTEX PHARMACEUTIC from 2016 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | €17.58 Billion | €3.54 Billion | 0.201x | -32.22% |
| 2022-12-31 | €13.91 Billion | €4.13 Billion | 0.297x | +13.41% |
| 2021-12-31 | €10.10 Billion | €2.64 Billion | 0.262x | -30.12% |
| 2020-12-31 | €8.69 Billion | €3.25 Billion | 0.375x | +45.23% |
| 2019-12-31 | €6.09 Billion | €1.57 Billion | 0.258x | -9.96% |
| 2018-12-31 | €4.44 Billion | €1.27 Billion | 0.286x | -30.77% |
| 2017-12-31 | €2.04 Billion | €844.94 Million | 0.414x | +134.49% |
| 2016-12-31 | €1.34 Billion | €236.10 Million | 0.176x | -- |